For informational purposes only — not investment advice

← Back to signals

BRKR

LONGINSIDER SELL

BRUKER CORP

Research: Finviz ↗·Perplexity ↗

Funds
3
Score
3.98
vs SPY
-10.9%
Stock return (since Q-end)
-6.5%
SPY return (since Q-end)
+4.5%
Current price
$56.25
Days to cover (short int.)
5.1d↓-0.7%
as of 2026-09-30

News Summary

Neutral

Bruker returned to organic revenue growth in Q2 2026 (+2.8% organically) with strong BSI segment bookings (+10%), but the stock fell 16.8% post-earnings due to a $135M goodwill impairment charge in struggling automation and spatial biology businesses and modest revenue miss. FY2026 guidance remains largely unchanged at 3-4% growth, though management signaled optimism for 2027 with expectations of 100+ bps margin improvement and double-digit EPS growth, creating a mixed near-term/long-term outlook.

Red flags

  • •$135M non-cash goodwill impairment charges in automation and spatial biology segments indicating ongoing business headwinds
  • •Revenue fell short of expectations despite EPS beat, triggering significant 16.82% stock decline
  • •Organic growth of only 1-2% guidance for FY2026 remains anemic despite Q2 acceleration
  • •Automation and spatial biology businesses described as experiencing 'ongoing headwinds' with no clear turnaround timeline

Funds Buying (3)

FundManagerShares Held∆ SharesPosition Value% of FundQoQStatus
Sachem Head CapitalScott Ferguson2.9M+2.9M$175M3.6%—NEW
Viking GlobalAndreas Halvorsen893K+893K$54M0.2%—NEW
Glenview CapitalLarry Robbins252K+252K$15M0.3%—NEW

Shares Held and Position Value reflect total quarter-end holdings. ∆ Shares is the change from the prior quarter. % of Fund is the position's share of the fund's reported equity portfolio — it drives the size weighting in the conviction score.

Portfolio Context

Where BRKR ranks in each buying fund's book, and the positions immediately around it. What a holding sits next to often says more about the thesis than the position size does.

Sachem Head Capital

position #13 of this fund's book

  1. 10GDS Hldgs Ltd$261M
  2. 11Gildan Activewear Inc$188M
  3. 12GOLAR LNG LTD$180M
  4. 13Bruker Corp$175M
  5. 14STMicroelectronics N V$165M
  6. 15Bitdeer Technologies Group$153M
  7. 16Twilio Inc$128M
Glenview Capital

position #36 of this fund's book

  1. 33BAKER HUGHES COMPANY$27M
  2. 34ELEVANCE HEALTH INC FORMERLY$26M
  3. 35MICROCHIP TECHNOLOGY INC.$24M
  4. 36BRUKER CORP$15M
  5. 37NOVARTIS AG$14M
  6. 38DIGITALOCEAN HLDGS INC$13M
  7. 39PRIMO BRANDS CORPORATION$10M

Values are quarter-end position sizes. Shown only for funds where BRKR ranks inside their 40 largest equity positions — below that, neighbouring names carry no signal. Adjacency is an inference about a fund's reasoning, not a disclosure of it.

Insider Activity

NameTitleTypeSharesPriceValueFiledSrc
Munch MarkEXEC VP&PRES BRUKER NANO INC.SELL2K$52.87$0.11M2026-09-15↗
Pusch WolfgangPresident BMID GroupSELL3K$56.90$0.20M2026-08-17↗
Munch MarkEXEC VP&PRES BRUKER NANO INC.SELL2K$57.60$0.12M2026-08-14↗
Munch MarkEXEC VP&PRES BRUKER NANO INC.SELL2K$60.25$0.12M2026-07-15↗

Beneficial Ownership (13D/13G)

FilerFormShares% of ClassFiledSrc
FMR LLCSC 13G/A23.3M15.0%2026-08-06↗
ORBIS INVESTMENT MANAGEMENT LTDSC 13G/A16.9M11.1%2026-05-15↗
FMR LLCSC 13G/A19.2M12.4%2026-05-06↗

SC 13D = active intent to influence control (10-day filing deadline after crossing 5%). SC 13G = passive accumulation, no intent to influence control.